Printer Friendly

FUJISAWA USA ANNOUNCES INTEGRATION OF NATIONAL ACCOUNTS DEPARTMENT

 DEERFIELD, Ill., April 21 /PRNewswire/ -- Fujisawa USA today announced the integration of its proprietary and multi-source national accounts departments into the newly formed Fujisawa USA Corporate Marketing Department. This follows the recent administrative consolidation of Fujisawa Pharmaceutical Company and Lyphomed under the parent company. National accounts customers are typically multi- location hospital and alternate site systems that purchase pharmaceuticals in large buying groups.
 "The corporate marketing department enforces Fujisawa USA's corporate commitment to fostering partnerships with customers to accomplish their strategic purchasing goals," said Dr. Hatsuo Aoki, chief executive officer, Fujisawa USA. "The department reports to Thomas Shea, who has been named senior director, corporate marketing."
 Shea added, "Under this arrangement, our key customers will enjoy more efficient service and, more important, one point of contact for all proprietary and multi-source pharmaceutical needs."
 Other key people in the new corporate marketing department are: Rick Isaac, manager, corporate sales-West; Steven Smith, manager, corporate sales-Midwest; and Edward McManus, manager, corporate sales- East.
 Headquartered in Deerfield, Fujisawa USA, Inc., is a subsidiary of Fujisawa Pharmaceutical Ltd., a research-based manufacturer of proprietary and multi-source pharmaceutical products in Osaka, Japan.
 -0- 4/21/93
 /CONTACT: Pat Walsh, 708-317-8849, or Paula Waters, 312-329-9292, both for Fujisawa USA/


CO: Fujisawa USA Inc.; Fujisawa Pharmaceutical Ltd. ST: Illinois IN: MTC SU: RCN

CK -- NY033 -- 8596 04/21/93 10:07 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1993
Words:223
Previous Article:GRUMMAN TO PURCHASE COMMON SHARES
Next Article:DNAP ISOLATES ACIDITY-CONTROLLING GENE -FIRST TIME GENE ISOLATION METHOD DEMONSTRATED IN HIGHER PLANTS-
Topics:


Related Articles
FUJISAWA ANNOUNCES REORGANIZATION AND SENIOR EXECUTIVE APPOINTMENTS
FUJISAWA USA SELLS PUERTO RICO PLANT TO CHIRON CORPORATION
FUJISAWA SUBMITS NEW DRUG APPLICATIONS TO FDA FOR FK-506
FUJISAWA USA UNIFIES SALES AND MARKETING OPERATIONS
FUJISAWA USA APPOINTS HERRICK TO MARKET PLANNING POST
FUJISAWA RECEIVES FDA CLEARANCE FOR NEW TRANSPLANT DRUG
/C O R R E C T I O N -- FUJISAWA/
FUJISAWA USA INITIATES CLINICAL TRIALS FOR AMBISOME
FUJISAWA USA, INC. ANNOUNCES INITIATION OF MAJOR PHASE III TRIAL TO EVALUTE AMBISOME
FUJISAWA USA, INC. APPOINTS NEW CEO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters